Human Anti-Bevacizumab Antibody inhibition ELISAEnlarge
A microtiter plate was coated overnight with recombinant human VEGF protein at a concentration of 1 µg/ml. After washing and blocking with PBST+5% BSA, a pre-incubated mixture of bevacizumab (0.3 µg/ml) plus increasing concentrations of Human Anti-Bevacizumab Antibody, clone AbD17976 (HCA182) in the monovalent Fab format was added. Free bevacizumab, still capable of binding to the human VEGF coated plate was detected using Mouse Anti-Human IgG (Fc) CH2 Domain:HRP (MCA647P) in HISPEC Assay diluent (BUF049A) followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.